Accessibility Menu
Hexima logo

Hexima(ASX) HXL

Market CapA$542.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-93%
5 YearN/A
1 Year-41%
1 Month-24%
A$0.03
+0.00%
+0.00Today
Hexima last closing stock price
MetricPriceDate
Last closeAUD 0.032024-10-22
Hexima stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%AUD 0.032024-10-14
1 month-23.53%AUD 0.042024-09-19
3 month-31.58%AUD 0.042024-07-24
Year to date-27.78%AUD 0.042023-12-20
1 year-40.91%AUD 0.052023-10-23
3 year-96.58%AUD 0.822021-10-21
Since inception-93.33%AUD 0.422020-12-01

Hexima Financials at a Glance

Market Cap

A$542.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$0.00

Net Income (TTM)

-A$1.18M

EPS (TTM)

-A$0.00

P/E Ratio

-8.67

Dividend

A$0.00

Beta (Volatility)

0.23 (Low)

Price

A$0.03

Volume

0

Open

A$0.03

Previous Close

A$0.03

Daily Range

A$0.03 - A$0.03

52-Week Range

A$0.01 - A$0.05

Estimated Earnings Date

Aug 27, 2026

HXL News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hexima

Hexima Limited is a biotechnology firm dedicated to the discovery and advancement of plant-derived proteins and peptides for medical applications in humans. The company's primary drug candidate, pezadeftide, is currently undergoing Phase IIb clinical evaluations in Australia and New Zealand to treat fungal toenail infections.

Products and Services
  • Pezadeftide, a plant defensin targeting fungal infections
  • Research and development of plant-derived therapeutic proteins
  • Innovative solutions for medical applications in human health
Growth Outlook
  • Ongoing Phase IIb trials for pezadeftide show potential for market entry
  • Strong focus on plant-derived therapies aligns with growing health trends
  • Increasing interest in biotechnology investments supports future growth
Financial Highlights
  • Recent quarterly revenue of AUD 30,837 indicates operational activity
  • Cash and cash equivalents reached AUD 1,912,951, providing liquidity
  • TTM cash flow metrics show a current ratio of 38.26, indicating strong short-term financial health
Hexima Limited operates in the dynamic biotechnology sector, focusing on innovative solutions derived from plant sources. The company's lead candidate, pezadeftide, is positioned to address a significant medical need, particularly in treating fungal infections. The ongoing clinical trials are crucial for validating the efficacy and safety of this treatment, which could pave the way for commercialization. The growth outlook for Hexima is promising, driven by the increasing demand for plant-based therapies and the company's strategic focus on research and development. The biotechnology sector is witnessing heightened interest from investors, which may further enhance Hexima's potential for growth. Financially, Hexima has demonstrated resilience with a recent quarterly revenue, indicating operational activity. The company's cash position is robust, providing a solid foundation for ongoing research and development efforts. The current ratio reflects a strong ability to meet short-term obligations, positioning Hexima favorably in the competitive biotechnology landscape.
AI Generated • Aug 23, 2026

Industry

Biotechnology

CEO

Geoffrey Paul Kempler

Headquarters

Carlton, VIC 3053, AU

HXL Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-14.90%

Return on Capital

-18.96%

Return on Assets

-14.51%

Earnings Yield

-11.53%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$542.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

41.76M

Volume

0

Avg. Volume

0

Financials (TTM)

Gross Profit

A$0.00

Operating Income

-A$981.34K

EBITDA

-A$1.21M

Operating Cash Flow

-A$839.15K

Capital Expenditure

A$0.00

Free Cash Flow

-A$839.15K

Cash & ST Invst.

A$1.54M

Total Debt

A$0.00

Hexima Performance Analysis

Hexima annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
20262026-06-30AUD 0N/A
Hexima sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-100.0%
Q22024-12-31N/A
Q42025-06-30N/A
Q22025-12-31N/A
Hexima annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.01-82.5%
20242024-06-30AUD -0.01-51.3%
20252025-06-30AUD -0.00-46.4%
20262026-06-30AUD -0.00-50.0%
Hexima sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42024-06-30-43.5%
Q22024-12-3127.3%
Q42025-06-3075.0%
Q22025-12-31100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

A$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

A$542.90KMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

-A$128.57K

+66.6%

EBITDA

-A$152.14K

+67.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$1.54M

-61.2%

Total Debt

A$0.00

N/A

Accounts Receivable

A$6.89K

-99.1%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-14.51%

N/A

Return on Invested Capital

-17.66%

N/A

Free Cash Flow

-A$123.56K

+72.8%

Operating Cash Flow

-A$123.56K

+72.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TSN.AXThe Sustainable Nutrition Group Ltd
A$0.01+25.00%
UCM.AXUscom Limited
A$0.01+9.09%
AMT.AXAllegra Medical Technologies Limited
A$0.03+0.00%
RGS.AXRegeneus Ltd
A$0.01+33.33%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$103.60+0.08%
BNCCea Industries
$4.80+0.38%
NVDANvidia
$226.92-0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.71+0.06%

Questions About HXL

What is the current price of Hexima?

Hexima is trading at A$0.03 per share.

What is the 52-week range for Hexima?

Over the past 52 weeks, Hexima has traded between A$0.01 and A$0.05.

How much debt does Hexima have?

As of the most recent reporting period, Hexima reported total debt of A$0.00.

How much cash does Hexima have on hand?

Hexima reported A$258.32K in cash and cash equivalents in its most recent financial results.

What is Hexima’s dividend yield?

Hexima does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.